Jump to content
Sclero Forums

Search the Community

Showing results for tags 'sle'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 5 results

  1. Analysis of serum macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase in systemic sclerosis (SSc). Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in healthy controls and systemic lupus erythematosus patients. PubMed, Clin Transl Immunology, 2018 Dec 6;7(12):e1042. (Also see Cytokines) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Therapeutic Applications of Mesenchymal Stem Cells (MSCs) for Systemic Lupus Erythematosus (SLE). The immuno–modulatory and regenerative characteristics of MSCs make them as one promising candidate for treating SLE. PubMed, Adv Exp Med Biol, 05/17/2018. (Also see Stem Cell Transplantation) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Serum level of DNase1l3 in patients with dermatomyositis/polymyositis (DM/PM), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and its association with disease activity. A significant reduction was found in serum DNase1l3 level in DM/PM and SLE, which may associate with clinic features and disease activity. PubMed, Clin Exp Med, 12/30/2016. (Also see Dermatomyositis and Polymyositis, Research on Systemic Lupus Erythematosus and Causes of Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Defining low disease activity (LDA) in systemic lupus erythematosus (SLE). LDA and remission groups had similar short term outcomes and both had better outcomes and prognosis than the high disease activity group. Wiley Online Library, Arthritis Care and Research, 10/01/2016. (Also see What is Systemic Lupus Erythematosus (SLE)?) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Fatigue in systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease often characterized by fatigue, with significant effects on physical functioning and wellbeing. Int J Clin Rheumtol. 2012 Apr 1;7(2):217-227. (Also see: Fatigue and Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...